Abstract: Risankizumab-rzaa (Skyrizi^®; AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy. Four pivotal Phase III trials: UltIMMa-1, UltIMMa-2, IMMhance, and IMMvent have demonstrated efficacy and safety in patients with moderate-to-severe plaque psoriasis. This review highlights important findings from these and other clinical trials that have evaluated risankizumab. In addition, we discuss the mechanism of action, pharmacokinetics/pharmacodynamics, dosing recommendations, drug interactions, other potential indications, and ongoing clinical trials.

Keywords: risankizumab, plaque psoriasis, IL-23 inhibitor, biologics, safety, efficacy


中文翻译：

---

Risankizumab-rzaa治疗斑块状牛皮癣的临床评价

摘要： Risankizumab-rzaa（Skyrizi ^® ;艾伯维）是人源化的IgG单克隆抗体针对白细胞介素23p19的（IL-23p19的）指示用于成年人谁是用于全身治疗或光线疗法的候选治疗中度至重度银屑病的。四个关键的III期试验：UltIMMa-1，UltIMMa-2，IMMhance和IMMvent已证明对中度至重度斑块状牛皮癣患者具有疗效和安全性。这篇综述重点介绍了这些和其他评估risankizumab的临床试验的重要发现。此外，我们讨论了作用机理，药代动力学/药效学，给药建议，药物相互作用，其他潜在适应症以及正在进行的临床试验。

关键字： risankizumab，斑块状牛皮癣，IL-23抑制剂，生物制剂，安全性，功效